0000899243-23-015960.txt : 20230620 0000899243-23-015960.hdr.sgml : 20230620 20230620161509 ACCESSION NUMBER: 0000899243-23-015960 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230615 FILED AS OF DATE: 20230620 DATE AS OF CHANGE: 20230620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hrustanovic Gorjan CENTRAL INDEX KEY: 0001821194 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39460 FILM NUMBER: 231025230 MAIL ADDRESS: STREET 1: C/O KYMERA THERAPEUTICS, INC. STREET 2: 200 ARSENAL YARDS, SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kymera Therapeutics, Inc. CENTRAL INDEX KEY: 0001815442 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 812992166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 857-285-5314 MAIL ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-15 0 0001815442 Kymera Therapeutics, Inc. KYMR 0001821194 Hrustanovic Gorjan C/O KYMERA THERAPEUTICS, INC. 200 ARSENAL YARDS BLVD. SUITE 230 WATERTOWN MA 02472 1 0 0 0 0 Stock Option (Right to Buy) 27.67 2023-06-15 4 A 0 12000 0.00 A 2033-06-14 Common Stock 12000 12000 D The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders. The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. /s/ Bruce Jacobs, as Attorney-in-Fact 2023-06-20